Back to Search
Start Over
Emerging drugs in cutaneous T cell lymphoma.
- Source :
-
Expert opinion on emerging drugs [Expert Opin Emerg Drugs] 2008 Jun; Vol. 13 (2), pp. 345-61. - Publication Year :
- 2008
-
Abstract
- Background: Mycosis fungoides (MF) represents the most common type of primary cutaneous T cell-lymphomas (CTCL), which are characterized by a clonally proliferation of malignant CD4+ lymphocytes in the skin.<br />Objective: Skin-directed treatment regimens, like phototherapy and corticosteroids, are commonly used in early stages; systemic treatments and chemotherapies are used in advanced stages. Because conventional treatments usually end in a transient remission without curative results, there is a high need for new therapeutic strategies with acceptable side effects.<br />Methods: Literature and reference research was done by using the data bank PubMed, and updates of ongoing studies were taken out of ASCO and ASH annual meeting abstracts.<br />Results/conclusions: This article gives an overview of the various medications in current use, with emphasis on emerging drugs with novel therapeutic targets.
- Subjects :
- Antineoplastic Agents adverse effects
Antineoplastic Agents therapeutic use
CD4-Positive T-Lymphocytes metabolism
Glucocorticoids therapeutic use
Humans
Lymphoma, T-Cell, Cutaneous physiopathology
Mycosis Fungoides drug therapy
Mycosis Fungoides physiopathology
Phototherapy
Remission Induction
Antineoplastic Agents pharmacology
Drug Delivery Systems
Lymphoma, T-Cell, Cutaneous therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1744-7623
- Volume :
- 13
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Expert opinion on emerging drugs
- Publication Type :
- Academic Journal
- Accession number :
- 18537525
- Full Text :
- https://doi.org/10.1517/14728214.13.2.345